#United States #Cambrex #API Manufacturing #Drug Supply #Charles City

Cambrex’s Ambitious Investment Plans

Cambrex, a leading global contract development and manufacturing organization (CDMO), recently declared plans for a substantial investment of $120 million aimed at expanding its Active Pharmaceutical Ingredient (API) manufacturing capabilities in the United States. This strategic move is intended to address a growing demand for local drug production and to enhance the resilience of the pharmaceutical supply chain in the most significant pharmaceutical market worldwide.

Meeting Growing Market Needs

According to Thomas Loewald, CEO of Cambrex, there is an increasing demand from clients to localize the manufacturing of drugs within the U.S. "The local production of APIs is essential for ensuring the safety and resilience of the drug supply chain," Loewald stated. With this investment, Cambrex aims to provide support by significantly increasing its manufacturing capacity in response to the needs of its clients and various regulatory agencies.

Expansion of Manufacturing Capacity

The new investment will lead to a 40% increase in large-scale manufacturing capacity at Cambrex’s facility in Charles City, Iowa. This facility occupies 45 acres and specializes in producing a diverse range of APIs and pharmaceutical intermediates, including high-potency molecules and controlled substances. The facility expansion is set to enhance its already substantial production capabilities, which will be vital in satisfying the demands of increasing need for critical therapies marketed in the U.S.

As the pharmaceutical industry continues to evolve, Cambrex remains committed to maintaining stability in the domestic supply chain of medications. "With the rising demand for U.S.-produced critical therapies, Cambrex is focused on supporting long-term stability in pharmaceutical manufacturing in the country," added Loewald.

A Tradition of Investment

This recent commitment continues Cambrex’s tradition of investing in its drug development and manufacturing network. The company’s recent expansions over the past five years include:

• - January 2022: A new high-potency API manufacturing capability added to the Charles City facility.
• - April 2023: Launch of advanced laboratories designed for small to medium-scale clinical and commercial manufacturing in High Point, North Carolina, targeting rare disease treatments and orphan drug designations.
• - March 2025: Enhancement of manufacturing capabilities compliant with Current Good Manufacturing Practices (CGMP) for peptide therapies in Waltham, Massachusetts.

These ongoing investments underscore Cambrex's commitment to expanding its capabilities and meeting the changing demands of the pharmaceutical industry.

About Cambrex

With over 40 years of experience in pharmaceutical development and manufacturing, Cambrex provides comprehensive services that cover the entire lifecycle of pharmaceutical development and manufacturing, as well as robust analytical services and IND-enabling capabilities. Employing over 2,000 experts who cater to global clients across North America and Europe, Cambrex offers an array of specialized technologies and expertise, including continuous flow, controlled substances, peptide synthesis, solid-state science, material characterization, and highly potent APIs.

In conclusion, Cambrex's robust investment not only positions it to meet current market demands but also enhances its role as a pivotal player in the U.S. pharmaceutical landscape, ensuring greater security in drug supply chains for the future.